Industry news

Semaglutide may become the first GLP-1 therapy for CKD

semaglutide CKD

Semaglutide can reduce the risk of CKD events by 24%

Research has shown that treatment with Semaglutide can reduce the risk of CKD (chronic kidney disease) events by 24%. Cardiovascular death by 29%, EGFR significantly slows down the decline, cardiovascular risk decreases by 18%, and all-cause mortality rate decreases by 20%.

May 24, 2024, Novo Nordisk‘s latest data of Semaglutide in the treatment of chronic kidney disease with type 2 diabetes large phase III clinical FLOW was published in the New England Medical Journal. The main endpoint of the study was kidney disease (CKD) events (kidney failure such as dialysis, transplantation eGFR<15ml/min/1.73m2. Or eGFR decreased by more than 50% from baseline, or died.

Clinical trial of GLP-1 therapy for CKD

The FLOW clinical trial is a randomized, double-blind, placebo-controlled clinical trial. It aims to examine the effect of subcutaneous injection of Ozempic with a dose of 1.0 mg, as an adjunctive therapy of standard treatment. on the progress of preventing kidney injury in patients with CKD and type 2 diabetes, and on the risk of kidney and cardiovascular death compared with placebo. The trial recruited 3533 patients with CKD and type 2 diabetes.

The main endpoint of the experiment is a composite endpoint composed of multiple components, including the time when the estimated glomerular filtration rate (eGFR) continues to decrease by ≥ 50% compared to baseline. The time for eGFR to decrease to<15 mL/min/1.73 m2. Start chronic kidney replacement therapy (dialysis or kidney transplantation). Type 2 diabetes and chronic kidney disease patients die of kidney disease or cardiovascular disease. Key secondary endpoints include the annual rate of change in eGFR, major adverse cardiovascular events (non fatal myocardial infarction, non fatal stroke, cardiovascular death), and all-cause mortality.

Development prospects

According to the estimation of the World Health Organization (WHO). There are about 422 million people suffering from diabetes in the world. The human body’s inability to produce enough insulin caused this disease. Or to correctly use the insulin synthesized by the human body. It is greatly affecte the blood glucose regulation ability. In addition, type 2 diabetes patients also have a higher risk of suffering from other diseases. For example, type 2 diabetes patients have a 2-4 times higher risk of cardiovascular disease than healthy people. and about 40% of type 2 diabetes patients have CKD.

Leave a Reply

Your email address will not be published. Required fields are marked *